Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AtaiBeckley Inc. - Common Stock
(NQ:
ATAI
)
3.945
+0.125 (+3.27%)
Streaming Delayed Price
Updated: 12:55 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AtaiBeckley Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
↗
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
↗
June 09, 2024
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
Via
Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
↗
June 05, 2024
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Via
Benzinga
What's Going On With MindMed And Psychedelic Stocks?
↗
June 05, 2024
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024
↗
May 15, 2024
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Recap: ATAI Life Sciences Q4 Earnings
↗
March 28, 2024
Via
Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
↗
May 13, 2024
Via
Talk Markets
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
↗
May 09, 2024
Via
Benzinga
Topics
Cannabis
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
↗
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
↗
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
↗
April 19, 2024
Via
Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
↗
April 17, 2024
Via
Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
↗
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
↗
April 12, 2024
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via
Talk Markets
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
↗
April 03, 2024
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
April 03, 2024
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...
Via
Benzinga
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
↗
March 30, 2024
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via
Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
↗
March 29, 2024
Via
Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
↗
March 29, 2024
Via
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
↗
March 28, 2024
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023
↗
March 28, 2024
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
↗
March 20, 2024
Via
Benzinga
Topics
Economy
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
↗
March 16, 2024
Via
Benzinga
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
↗
March 11, 2024
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via
Talk Markets
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
↗
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
↗
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
↗
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
↗
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
↗
February 15, 2024
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
↗
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today